AFM
TTPH

Anson Funds Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Anson Funds Management’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-16,797
Closed -$380K – 65
2018
Q4 		$380K Buy
+16,797
New +$657K 0.22% 27
2016
Q1 		– Sell
-1,275
Closed -$256K – 97
2015
Q4 		$256K Buy
+1,275
New +$254K 0.08% 73

Other funds holding TTPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Anson Funds Management's TTPH Position: Q1 2019 in Review

Anson Funds Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q1 2019, closing a stake of 16,797 shares — an estimated $380K sold.

Anson Funds Management first reported a position in TTPH in Q4 2015 and held it in 2 quarters. The position peaked at $380K in Q4 2018. 78 funds tracked by Wall St. Rank hold TTPH as of Q1 2019.

  • Anson Funds Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Anson Funds Management sold 16,797 Tetraphase Pharmaceuticals, Inc. shares in Q1 2019, an estimated $380K.
  • Anson Funds Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2015 and held it in 2 quarters.
  • Anson Funds Management's Tetraphase Pharmaceuticals, Inc. position peaked at $380K in Q4 2018.
  • 78 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q1 2019.

Based on Anson Funds Management's 13F filing for Q1 2019, filed 15 May 2019.